Novo Nordisk A/S saw a 40% surge in sales of its diabetes and weight-loss drugs in India last month, after steep price cuts boosted demand for its branded treatments even as generic GLP-1 therapies flood the market.
Eli Lilly & Co. is seeking to raise about $8 billion from an investment-grade bond sale, according to people with direct knowledge of the matter, as part of the company’s effort to fund an acquisition spree.
